New vaccine aims to snuff out the common cold
NCT ID NCT07399132
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new vaccine called APL-10456 that targets rhinovirus, the main cause of the common cold. About 144 healthy adults, both younger (18-54) and older (55+), will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APL-10456-Vaccine
- What this could lead to
- If successful, this could lead to a vaccine that prevents common colds caused by rhinovirus.
- What could go wrong
- This is a very early Phase 1 trial with only 144 healthy volunteers. The vaccine may not produce a strong immune response or could have unexpected side effects. Success in early phases does not guarantee a usable vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINOVIRUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emeritus Research
Melbourne, Victoria, 3124, Australia
-
Veritus Research
Melbourne, Victoria, 3153, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.